EMA Authorised: Lytenava (bevacizumab) — Outlook Therapeutics NL B. V.

View source ↗

Summary

The EMA authorised Lytenava, a bevacizumab-based treatment for wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Lytenava (bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration. MAH: Outlook Therapeutics NL B. V.. Decision date: 04/02/2026